Wall Street analysts expect Natera Inc (NASDAQ:NTRA) to post $66.23 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Natera’s earnings. The lowest sales estimate is $65.50 million and the highest is $67.25 million. Natera reported sales of $56.66 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 16.9%. The company is expected to issue its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Natera will report full-year sales of $262.85 million for the current financial year, with estimates ranging from $259.50 million to $266.00 million. For the next financial year, analysts anticipate that the business will report sales of $328.14 million per share, with estimates ranging from $310.00 million to $340.32 million. Zacks’ sales averages are an average based on a survey of analysts that follow Natera.
Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.55). The company had revenue of $63.07 million during the quarter, compared to analyst estimates of $61.71 million. Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The firm’s revenue for the quarter was up 20.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.55) earnings per share.
In other Natera news, COO Steven Leonard Chapman sold 86,919 shares of the stock in a transaction dated Monday, June 25th. The shares were sold at an average price of $18.00, for a total transaction of $1,564,542.00. Following the completion of the transaction, the chief operating officer now owns 3,588 shares in the company, valued at $64,584. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Burkes Brophy sold 26,870 shares of the stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $18.29, for a total transaction of $491,452.30. The disclosure for this sale can be found here. Insiders have sold 115,797 shares of company stock valued at $2,080,794 in the last quarter. Company insiders own 13.18% of the company’s stock.
Large investors have recently modified their holdings of the business. Sofinnova Ventures Inc bought a new position in shares of Natera in the first quarter valued at approximately $28,742,000. Tygh Capital Management Inc. boosted its position in shares of Natera by 32.3% in the second quarter. Tygh Capital Management Inc. now owns 300,036 shares of the medical research company’s stock valued at $5,647,000 after acquiring an additional 73,301 shares during the period. Trexquant Investment LP bought a new position in shares of Natera in the first quarter valued at approximately $119,000. Schwab Charles Investment Management Inc. boosted its position in shares of Natera by 11.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 172,518 shares of the medical research company’s stock valued at $1,600,000 after acquiring an additional 18,051 shares during the period. Finally, EAM Investors LLC bought a new position in shares of Natera in the second quarter valued at approximately $3,868,000. Hedge funds and other institutional investors own 66.31% of the company’s stock.
NTRA opened at $28.93 on Tuesday. The stock has a market cap of $1.76 billion, a P/E ratio of -12.14 and a beta of 2.12. The company has a debt-to-equity ratio of -3.32, a current ratio of 1.69 and a quick ratio of 1.56. Natera has a fifty-two week low of $8.60 and a fifty-two week high of $29.62.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.